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The anatomical and functional characterization of somatostatin (SST) and somatostatin
receptors (SSTRs) within the spinal cord have been focused in the dorsal horn,
specifically in relation to sensory afferent processing. However, SST is also present
within the intermediolateral cell column (IML), which contains sympathetic preganglionic
neurons (SPN). We investigated the distribution of SSTR2 within the thoracic spinal cord
and show that SSTR2A and SSTR2B are expressed in the dorsal horn and on SPN and
non-SPN in or near the IML. The effects of activating spinal SSTR and SSTR2 were
sympathoinhibition, hypotension, bradycardia, as well as decreases in interscapular
brown adipose tissue temperature and expired CO2, in keeping with the well-described
inhibitory effects of activating SSTR receptors. These data indicate that spinal SST
can decrease sympathetic, cardiovascular and thermogenic activities. Unexpectedly
blockade of SSTR2 revealed that SST tonically mantains sympathetic, cardiovascular
and thermogenic functions, as activity in all measured parameters increased. In
addition, high doses of two antagonists evoked biphasic responses in sympathetic and
cardiovascular outflows where the initial excitatory effects were followed by profound but
transient falls in sympathetic nerve activity, heart rate and blood pressure. These latter
effects, together with our findings that SSTR2A are expressed on GABAergic, presumed
interneurons, are consistent with the idea that SST2R tonically influence a diffuse spinal
GABAergic network that regulates the sympathetic cardiovascular outflow. As described
here and elsewhere the source of tonically released spinal SST may be of intra- and/or
supra-spinal origin.
Keywords: somatostatin, spinal cord, autonomic, sympathetic, brown adipose tissue temperature
INTRODUCTION
Neuropeptides encoded by about 70 genes influence neuronal activity within the central nervous
system (Burbach, 2010). The inhibitory neuropeptide somatostatin (SST) is distributed widely
throughout the CNS, in its two biologically active forms, SST-14 and SST-28. Within the spinal
cord SST immunoreactive terminals are present in the dorsal horn which receives primary
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sensory information and the intermediolateral cell column
(IML), the major source of sympathetic preganglionic neurons
(SPN) (Krukoff, 1987; Patel, 1999; Schulz et al., 2000). SSTR1-
4 are present in the spinal cord (Segond von Banchet et al.,
1999; Schulz et al., 2000). The spinal distribution of SST and
somatostatin receptor (SSTR) suggests involvement in modifying
afferent information entering the dorsal horn and the activity of
the SPN. Although effects at the dorsal horn are well established
(Kuraishi et al., 1985; Sandkühler et al., 1990; Shi et al., 2014;
Takahashi et al., 2014), there has been no investigation into the
role SST exerts at the sympathetic outflow in the thoracic spinal
cord that may modify cardiovascular and/or metabolic activity.
Somatostatin modulates cardiovascular and metabolic
functions at higher levels of the neuraxis (Burke et al., 2008;
Cote-Vélez et al., 2017). For example, inhibiting ventral
medullary nuclei with SST results in apneusis, bradycardia,
hypotension sympathoinhibition, and attenuation of chemo-
and somatosympathetic reflexes (Burke et al., 2008, 2010) and
these effects were blocked using selective SSTR2 antagonists
(Burke et al., 2008). Furthermore all premotor sympathetic
cell groups contain SST including those in the ventral medulla
(Millhorn et al., 1987; Strack et al., 1989a), serotonergic neurons
of the raphe (Loewy and McKellar, 1981; Chiba and Masuko,
1989), the A5 cell group (Strack et al., 1989a) and neurons in the
paraventricular nucleus of the hypothalamus (PVN) (Sawchenko
and Swanson, 1982). These data further suggest that SST in the
spinal cord influences sympathetic function.
We explored this hypothesis. Our initial targets were
SSTR1 and SSTR2 as these are the most abundant SSTR
in rodents (Gunther et al., 2018), however, as SSTR1 is
found presynaptically, acting often as an autoreceptor,
we focused our attention on SSTR2. We identified the
distribution of SSTR2A and SSTR2B-like immunoreactivity
within the thoracic spinal cord and showed expression in
the dorsal horn and on SPN together with an association
of SSTR2A with GABAergic neurons. We investigated the
functional effects of SST and an SSTR2 agonist applied
intrathecally to the upper thoracic spinal cord on sympathetic,
cardiovascular and thermogenic outflows and determined
the functional consequences of blocking SSTR2. Our data
suggest that, within the thoracic spinal cord, SST acts on
SSTR2 expressing sympathetic and dorsal horn neurons to
tonically suppress sympathetic activity and interscapular
brown adipose tissue (iBAT) thermogenesis. Additionally, we
propose that SST tonically suppresses, via SSTR2, a spinal
network of GABAergic neurons that modulates sympathetic and
cardiovascular outputs.
MATERIALS AND METHODS
Adult, male, Sprague Dawley rats (450–550 g; Animal Resources
Centre, Perth, Australia) were used in accordance with the
guidelines of the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes and all procedures
were approved by the Animal Care and Ethics Committee and
Biosafety Committee, of Macquarie University.
Anatomical Experiments
Immunohistochemistry
Immunohistochemistry was conducted as described previously
(Bowman et al., 2013; Parker et al., 2013). Briefly, pentobarbitone
anesthetized rats (80 mg/kg, n = 4) were perfused transcardially
with saline followed by 4% paraformaldehyde (PFA) in phosphate
buffer (pH 7.4, fixative). Spinal cords (C8-T3 and T4-T10), placed
in fixative overnight, then sectioned parasagittally or coronally
(50 µm) using a vibrating microtome. Free-floating sections
were washed 3 × 30 min in TPBS (Tris-HCl 10 mM, sodium
phosphate buffer 10 mM, 0.9% NaCl, pH 7.4) then incubated
48 h at 4◦C in TPBS with 0.01% merthiolate (TPBSm) containing
5% normal horse serum and primary antibodies to detect SPN
(goat anti-choline acetyl transferase [ChAT], 1:800, #AB144P,
RRID:AB_2079751, Millipore, United States) and SSTR2A
(1:100, #SS-800, RRID:AB_2491103, Biotrend, Germany) or
SSTR2B receptor (1:750, #SS-810, Biotrend, Germany). After
three washes, sections were incubated overnight at 4◦C in TPBSm
containing 2% normal horse serum and secondary antisera:
Alexa Fluor R© 488-conjugated donkey anti-goat (#A-11055,
RRID:AB_2534102, Invitrogen, Australia) and Cy3-conjugated
donkey anti-rabbit (#711-165-152, RRID:AB_2307443, Jackson
ImmunoResearch, United States). Sections were washed,
mounted with FluoromountTM mounting medium (#K024,
Diagnostic Biosystems, Pleasanton, CA, United States) and
coverslipped when almost dry.
Retrograde Tracing
Retrograde tracing was carried out as described previously
(Bowman and Goodchild, 2015) with the tissue used here
acquired from the animals used in this previous study. Rats
(n = 12) were anesthetized with ketamine (75 mg/kg) and
medetomidine (0.5 mg/kg, ip). Cephazolin (200 mg, im) and
carprofen (2.5 mg/kg sc) were administered. Animals were
secured in a stereotaxic frame and a laminectomy exposed
T2. Cholera toxin B (CTB, 1% 2 × 100 nl injections, #103C,
List Biologicals, United States) was bilaterally microinjected
into the spinal cord centered on the lateral horn. The
skin wound was closed, povidine-iodine (Betadine, Faulding
Pharmaceuticals, Australia) applied to the area and the
animal was administered atipamezole (1 mg/kg sc) and
monitored closely.
After 2 days, rats were reanesthetized with sodium
pentobarbital (80 mg/kg ip), perfused as described above
and brain and spinal cord were removed and placed fixative
overnight before processing. CTB injection sites within the spinal
cord were shown previously (Bowman and Goodchild, 2015).
Combined Immunohistochemistry and in situ
Hybridization
Combined immunohistochemistry and in situ hybridization
was carried out on brains and spinal cords cut coronally
using a microtome (VT1200S, Leica, Wetzlar, Germany; 40
and 100 µm, respectively). Spinal cord injection sites were
identified using a modified nickel intensified diaminobenzidine
(DAB) reaction as described and demonstrated previously
(Bowman and Goodchild, 2015).
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In brain sections fluorescent immunohistochemical detection
of CTB was conducted using a rabbit anti-CTB primary
antibody (1:5,000, #7927, RRID:AB_2313635, ViroStat,
Portland, ME, United States) in conjunction with detection
of mRNA using digoxigenin (DIG)-labeled riboprobes as
described previously (Kumar et al., 2010; Bowman et al.,
2013; Bowman and Goodchild, 2015). Sense (forward) and
antisense (reverse) riboprobes for preprosomatostatin (PPS)
were designed as previously published (Burke et al., 2008), with
a T7 promoter attached to the 5′ end of the antisense primer
and an SP6 promoter attached to the sense primer as follows
(promoters in uppercase):
Forward: GGATCCATTTAGGTGACACTATAGAAGctca
agctcggctgtctgag
Reverse: GAATTCTAATACGACTCACTATAGGGAGAgg
aggagagggatcagaggt
Detection of GAD67 mRNA in SSTR2A expressing neurons
of the spinal cord was conducted as described above, in 40 µm
thick parasagittal or coronal sections of spinal cord segments C8-
T3 and T4-T10. A primary antibody raised in rabbit was used
to target SSTR2A (#SS-800, Biotrend, Germany), and a donkey
anti-rabbit secondary antibody (Cy3-conjugated, #711-165-152,
Jackson ImmunoResearch, United States) for visualization. The
following sense and antisense primers were designed for GAD67
riboprobe (promoters in uppercase) as described previously
(Burke et al., 2008; Bowman et al., 2013):
Forward: GGATCCATTTAGGTGACACTATAGAAGttatg
tcaatgcaaccgc
Reverse: GAATTCTAATACGACTCACTATAGGGAGAcc
caacctctctatttcctc
Imaging and Analysis
All imaging was conducted using an AxioImager Z1 (Carl
Zeiss, Germany). Spinal cord sections were scanned for ChAT-
ir neurons within the lateral horn or close to the central canal.
ChAT-ir nests were imaged and quantified in C8-T3 sections, by
counting the number of ChAT-immunoreactive (-ir) cells which
expressed SSTR2A in each animal. Results were expressed as
mean percentage of ChAT-ir cells expressing SSTR2A± SEM.
The presence of CTB-ir and PPS mRNA expression were
identified in brain sections containing the presympathetic cell
groups: the caudal raphe (pallidus, obscurus and magnus),
RVMM (paragigantocellular and parapyramidal groups), RVLM,
A5 region and PVN. After scanning the rostrocaudal extent of
each premotor group, the Bregma level which had the highest
expression of CTB was identified. One or two additional sections
were also selected for inclusion in analysis, according to the
longitudinal spread of CTB labeling within a cell group. Thus
cell groups with a longer rostrocaudal extent of CTB-ir were
allocated three Bregma levels for analysis, while those with
a smaller rostrocaudal CTB-ir distribution were allocated two
levels. Sections from the following Bregma levels were analyzed
for double labeling: the raphe was analyzed at −13.90, −12.12
and −11.52 mm; the RVMM analyzed at −13.56, −12.96 and
−12.24 mm; the RVLM analyzed at −12.36 and −12.00 mm;
the A5 region analyzed at −10.20 and −9.72 mm and the
PVN analyzed at −2.04 and −1.72 mm. Cells were counted
bilaterally, and the number of CTB-ir neurons expressing
PPS mRNA was determined. Results were expressed as the
average percent (±SEM) of retrogradely labeled cells expressing
PPS in each region.
Physiological Experiments
Surgical Preparation
Surgical preparation was conducted as described previously
(Burke et al., 2008, 2010). Rats were anesthetized with urethane
(ip, 10% in saline 1.3 g/kg) and core temperature was monitored
via flexible rectal thermistor and maintained (36.5–37◦C)
using a heating blanket (Harvard Apparatus, Holliston, MA,
United States). Thirty minutes before intrathecal injection, core
temperature was adjusted to 36◦C to generate brown adipose
tissue thermogenesis, as previously described (Tupone et al.,
2011). The right femoral artery and jugular vein were cannulated
for measurement of arterial pressure and administration of
drugs and saline, respectively. Animals were vagotomized and
intubated for artificial oxygen-enriched ventilation (rodent
respirator #7025, UGO Basile, Italy), and secured in a stereotaxic
frame. Rats were paralyzed with pancuronium bromide [0.8 mg
iv, followed by an infusion (0.1 mg/ml in saline) at 2 ml/h].
End-tidal CO2 (Capstar-100, CWE Inc., PA, United States) was
maintained between 3.5 and 4.5% under control conditions.
Heart rate was calculated using the R wave of ECG recordings.
Recordings of efferent sympathetic nerve activity (SNA) were
made from the cut, left greater splanchnic nerve using bipolar
silver wire electrodes. Signals were amplified (BMA-400, #09-
03010, CWE Inc., United States), band pass filtered (0.1 Hz–
3 kHz) and digitized for recording using Spike2 software
(Cambridge Electronic Design Ltd., Cambridge, England). Data
were normalized for comparison by taking the activity present
at the nadir following euthanasia (see below) as zero nerve
activity and 100% nerve activity was taken as the average
of activity 5 min prior to intrathecal drug injection. The
temperature of left and right iBAT deposits was measured
using T2 thermocouple probes (#BT-1, Physitemp, Clifton, NJ,
United States) attached to a T-type Pod (#ML312 & #ML305,
ADInstruments, Sydney, Australia) connected to a PowerLab
(30 series, ADInstruments, Sydney, Australia) then digitized for
recording. Thus, three sympathetic outflows were monitored: HR
(vagotomised), splanchnic SNA and iBAT temperature.
In two animals the adrenal glands were removed bilaterally via
the retroperitoneal cavity and the adrenal blood vessels ligated.
Intrathecal Drug Administration
Dura beneath the atlanto-occipital membrane was incised, and
a catheter (od 0.61; id 0.28 mm) inserted in the sub-arachnoid
space and advanced to spinal level T5–T6, as described previously
(Bowman and Goodchild, 2015).
Intrathecal injections of drug (agonists (SST 1 mM [#H-
1490.0005, Auspep, Australia], seglitide 1 mM [#S1316, Sigma
Aldrich, United States]) and antagonists (BIM-23627 (45 µM,
150 µM, 450 µM and 1.5 mM) [#H-5886.1000, Bachem,
Switzerland], CYN-154806 1 mM [D Tyr form, #1843, Tocris,
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United Kingdom])) or vehicle (saline or phosphate buffered
saline, PBS, pH 7.4) were conducted using a Hamilton syringe.
Five microliter of drug or vehicle, flushed with 7 µl of vehicle,
was injected over 10–15 s. MAP, HR, splanchnic SNA, iBAT
temperature, end tidal CO2 and core temperature were recorded
for at least 60 min following injection. The concentration of SST
was the same as used previously (Burke et al., 2008).
The animals were then euthanized with 3 M KCl (0.3 ml iv),
and the level of nerve activity recorded, and a laminectomy was
performed to confirm the position of the catheter tip.
Data Analysis
Electrophysiological data were analyzed as the peak change
from baseline (pre-injection) values. Data are presented as the
mean ± the SEM. GraphPad Prism and/or SPSS (Statistical
Package for the Social Sciences) were used for statistical analysis
and the data were considered significant at p< 0.05. Where peak
changes due to drug were compared to vehicle, Student’s t-test
was used to compare responses. Where the effects of the different
doses of antagonist were compared, mean peak and trough
responses across treatment groups were analyzed separately via
analysis of variance (ANOVA). Dunnett’s t-test adjustments were
used to compare individual responses to control (saline). A
priori polynomial contrasts were used to assess systematic trends
(linear, quadratic, etc.) across treatment means for the main
dependent variable.
RESULTS
SSTR2 Are Densely Expressed in the
Dorsal Horn, on SPN and on GABAergic
Neurons in the Thoracic Spinal Cord
Although SST terminals have been described around SPN no
SSTR have been described here thus, we sought to identify the
location of SSTR2A and SSTR2B in thoracic spinal cord. Dense
immunolabeling of SSTR2A and SST was found in lamina II of
the dorsal horn (Figures 1A,B) as has been previously described
(Schulz et al., 1998; Todd, 2017). Some, but not all, ChAT labeled
SPN in the IML and around the central canal expressed SSTR2A-
like immunoreactivity (Figures 1C–F). About 10% of SPN in the
IML expressed SSTR2A-like immunoreactivity in C8-T3 spinal
cord segments (10.1± 1.2% of 582 SPN counted, n = 3) with some
nests having multiple SSTR2A expressing neurons (Figures 1E,F)
but many having none. Non-ChAT labeled neurons both close
to, and more distant, from the IML, also expressed SSTR2A-like
immunoreactivity (Figures 1F,G).
To determine whether non-ChAT SSTR2A positive neurons
were GABAergic, in situ hybridization for GAD67 mRNA was
combined with SSTR2A immunolabeling (Figure 2A). SSTR2A-
like immunoreactivity was co-expressed with GAD67 mRNA
in some neurons in the dorsal horn, as previously described
(Todd, 2017) (Figure 2B) including lamina III (Figure 2E),
the dorsolateral funiculus (Figure 2C), adjacent to central canal
(Figure 2D), as well as in some star shaped neurons close to the
IML (Figure 2F).
SSTR2B immunolabeling was also present in lamina II
of the dorsal horn and in the ventral horn (Figure 3)
as previously described (Schulz et al., 1998). More diffuse
SSTR2B immunolabeling was observed in other parts of
the gray matter [as previously described (Schulz et al.,
1998)] with some ChAT labeled SPN expressing SSTR2B-like
immunoreactivity (Figure 3B). Accurate quantification was not
possible due to the diffuse nature of the SSTR2B expression
as previously described (Schulz et al., 1998). ChAT positive
motoneurons in the ventral horn clearly expressed SSTR2B-
like immunoreactivity (Figures 3A,D) but not SSTR2A-like
immunoreactivity (see Figure 1A).
Thus, immunolabeling for SSTR2 is present in the spinal
cord: in the dorsal horn (SSTR2A & SSTR2B) and ventral horn
(SSTR2B); on some GABAergic, likely, interneurons and on SPN
(SSTR2A & SSTR2B), with the latter suggesting their activation
influences sympathetic outputs.
PPS mRNA Is Found in all Sympathetic
Premotor Cell Groups
To assess supraspinal sources of SST that could directly influence
SPN, premotor sympathetic cell groups were examined to
determine if they expressed PPS mRNA (n = 3–4). Examples of
double labeling in the raphe pallidus (Figure 4A), raphe magnus
(Figure 4B) and RVMM (Figure 4C) reflect the larger proportion
of CTB-labeled cells double labeled for PPS mRNA in these
regions (Figure 4D): raphe pallidus (13.9 ± 3.8% of 302 CTB-
ir neurons), raphe magnus, (11.7± 2.9% of 493 CTB-ir neurons),
raphe obscurus (7.9 ± 1.4% of 140 CTB-ir neurons), the RVMM
(12.5 ± 3.0% of 433 CTB-ir neurons) and the region containing
the A5 group (26.9 ± 3.0% CTB-ir of 74 neurons), compared to
the RVLM (2.6 ± 1.0% of 210 CTB-ir neurons) and the PVN
(1.4± 0.7% of 769 CTB-ir neurons).
Thus, all major premotor sympathetic cell groups have the
potential to release SST at SPN with the greatest innervation
arising from the brainstem. The predominant SST projection,
representing 81% of all PPS mRNA + CTB-ir neurons, arises
from the midline raphe/RVMM regions of the brainstem.
SST or Selective Activation of SSTR2 in
the Thoracic Spinal Cord Reduces
Cardiovascular, Sympathetic and
Thermogenic Activity
As some SPN expressed SST2R-like immunoreactivity and
potentially receive SST input from raphe/RVMM regions the
effects of intrathecal administration of SST (total volume 5 µl,
n = 8), at a dose previously used within the ventral medulla
to reduce autonomic outflows [1 mM; (Burke et al., 2008)],
was determined. Sympathetic, cardiovascular and thermogenic
parameters were decreased (Figure 5A). SST evoked significant
sympathoinhibition (−15.1 ± 3.8 vs −0.3 ± 1.1%, t(8) = 3.71;
p = 0.006), modest hypotension (−7.9 ± 1 vs −0.1 ± 1.0 mmHg,
t(10) = 5.38; p = 0.0003), and bradycardia (−41 ± 6 vs
0.5 ± 2 bpm, t(14) = 6.32; p < 0.0001), compared to
vehicle control (Figures 5A,C). Similarly, metabolic outflows
were reduced (Figures 5A,C), with a peak decrease of
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FIGURE 1 | SSTR2A are expressed in dorsal horn, on SPN and non-ChAT labeled neurons in the thoracic spinal cord. (A) Coronal section of thoracic spinal cord
showing distribution of SSTR2A-like (magenta), SST (blue) and ChAT immunolabeling (green). (B) Dorsal horn showing overlapping SSTR2-like and SST labeling.
(C) Intermediolateral cell column (IML) containing ChAT labeled SPN with some exhibiting SSTR2A-like immunoreactivity (filled arrows). (D) Central autonomic area
containing some SSTR2A expressing ChAT labeled SPN (filled arrows). (E–G) “Nests” of ChAT labeled SPN some of which co-express SSTR2A-like labeling (filled
arrows). Scale bars = 20 µm. Open arrows indicate non-ChAT SSTR2A labeled neurons close to or adjacent to SPN.
−0.38 ± 0.11◦C in iBAT temperature and −0.24 ± 0.09%
in expired CO2 compared to vehicle (iBAT = 0.06 ± 0.05◦C,
t(6) = 4.14; p = 0.0061, and expired CO2 = 0.00 ± 0.01%,
t(6) = 2.61; p = 0.04, respectively). Note that core temperature
was maintained at 36◦ ensuring iBAT thermogenesis was
active (Tupone et al., 2011). Administration of 45 µM
SST (n = 2) elicited a smaller bradycardic response (−19
bpm) but did not alter any other parameter measured
(data not shown). PBS used as a vehicle control did not
change any parameters measured, as previously observed
(Bowman and Goodchild, 2015).
To determine whether SSTR2 contributed to the responses
observed, the SSTR2 selective agonist Seglitide was administered
intrathecally (5 µl, 1 mM, n = 7) and decreased cardiovascular
and thermogenic outflows measured (Figures 5B,C). As observed
with SST, application of Seglitide resulted in sympathoinhibition
(−14.0 ± 4.1 vs −2.54 ± 0.77%; t(12) = 2.73; p = 0.018),
bradycardia (−30 ± 4.7 vs −2.6 ± 1.2 bpm; t(12) = 5.68;
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FIGURE 2 | Some SSTR2A expression colocalises with GAD67 mRNA in thoracic spinal cord. (A) Coronal section of spinal cord showing SSTR2A-like
immunoreactivity (magenta) and GAD67 mRNA (black). Some neurons in dorsal horn (B), dorsolateral funiculus (C), central autonomic area (D) and lamina III (E)
co-express both markers. (F) Neuron adjacent to IML expressing SSTR2A-like immunoreactivity and GAD67 mRNA. Filled arrows indicate double-labeled neurons.
Scale bars for B–E = 50 µm and for F = 20 µm.
p = 0.0001) and hypotension (−8.7 ± 1.5 vs 1.3 ± 1.4 mmHg;
t(12) = 4.85; p = 0.0004) when compared to vehicle. Moreover,
decreases in iBAT temperature (−0.41 ± 0.10 vs 0.01 ± 0.03◦C;
t(6) = 3.91; p = 0.0079) and expired CO2 (−0.20 ± 0.03 vs
0.001 ± 0.01%; t(12) = 6.61; p < 0.0001) also resulted from
selective SSTR2 activation.
These data indicate that activation of SSTR, and specifically
SSTR2, in the spinal cord reduces sympathetic, cardiovascular
and thermogenic parameters.
Blockade of SSTR2 in the Spinal Cord
Increases Sympathetic, Cardiovascular
and Thermogenic Parameters
We then sought to determine whether SSTR2 expressing
spinal neurons tonically influence sympathetic, cardiovascular or
thermogenic activity.
Figure 6A shows representative responses to increasing
doses of the peptide antagonist BIM-23627 which exhibits high
affinity for SSTR2 (Tulipano et al., 2002). A low dose of
45 µM BIM-23627 had little effect on any parameter (data
not shown) whereas 150 µM BIM-23627 increased sympathetic,
cardiovascular (HR, MAP) and thermogenic (iBAT, expired CO2)
parameters with 450 µM amplifying these effects (Figure 6A).
Higher concentrations of BIM-23627 (450 µM and 1.5 mM)
produced a biphasic response, where the initial increase in
sympathetic and cardiovascular outflows was followed by a
secondary decrease in these parameters (Figure 6A).
Very similar effects in all parameters were evoked by CYN-
154806 (1 mM) (Figure 6B), also a peptide antagonist with a
high affinity for SST2R. Importantly with both antagonists all
parameters returned to baseline within∼75 min.
The dose response grouped data are shown in Figure 6C,
with the peak increase and subsequent nadir shown for each
dose of BIM-23627 [45 µM n = 2 (not shown), 150 µM n = 4–5,
450 µM n = 5–7, 1.5 mM n = 4–5] and for CYN-154806 (1 mM,
n = 3). These were compared to the largest change evoked
by vehicle (VEH).
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FIGURE 3 | SSTR2B in dorsal and ventral horns and diffusely in the IML in the thoracic spinal cord. (A) Coronal section of thoracic cord showing SSTR2B-like
(magenta) and ChAT (green) immunoreactivity. Clear membrane associated SSTR2B-like labeling is present dorsal and ventral (D) horns with diffuse labeling in
intermediolateral cell column (B) and central autonomic areas (C). Filled arrows indicate double-labeled neurons (white indicates SSTR2B-like immunoreactivity
appears membrane-bound, gray indicates diffuse SSTR immunoreactivity). Scale bars = 50 µm.
In relation to the peak sympathetic and cardiovascular
responses ANOVA revealed significant dose-dependent effects
on sSNA and HR (F(3,14) = 3.44, p = 0.044, and F(3,18) = 9.03,
p = 0.0007, respectively), but not MAP (F(3,14) = 2.58,
p = 0.095). A significant quadratic effect was observed on
peak sSNA (F(1,15) = 6.43, p < 0.05) and HR (F(1,18) = 17.53,
p < 0.0005), suggesting that selective SSTR2 inhibition
increased cardiovascular outflows before decreasing them. The
maximum increase occurred at 450 µM BIM-23627, where the
sympathoexcitatory (42.5± 11.3 vs 0.70± 3.30%, p< 0.05, n = 5),
and tachycardic (43.2 ± 4.5 vs 3.6 ± 3.0 bpm, p < 0.001, n = 7)
responses peaked, before returning toward baseline. Significant
tachycardia was also observed at the other doses (150 µmM;
32.5 ± 8.5 bpm, 1.5 mM; 27.0 ± 6.9 bpm, p < 0.05, n = 5
and 6, respectively).
With respect to the secondary decreased responses,
ANOVA revealed significant dose-dependent effects on
sSNA (F(3,14) = 11.84, p = 0.0004), MAP (F(3,14) = 4.972,
p = 0.012), and HR (F(3,15) = 8.24, p = 0.0018). In contrast
to the initial peaks, a linear effect was seen in the secondary
trough responses of sSNA (F(3,14) = 36.843, p < 0.0001),
HR (F(1,14) = 20.49, p < 0.0001), and MAP (F(1,14) = 14.67,
p < 0.005), suggesting that more SSTR2 were influenced or
were impacted for longer, resulting in significant cardiovascular
decline. Significant sympathoinhibition and hypotension were
evoked by 450µM and 1.5 mM BIM-23627 (sSNA:−49.15± 13.0
and −79.72 ± 3.10%, respectively, p < 0.01, MAP: −22.7 ± 7.7
and −24.0 ± 4.3 mmHg, respectively, p < 0.01), whereas heart
rate reached significance only at 1.5 mM (−71.7 ± 14.0 bpm,
p< 0.01), when compared to control.
With respect to thermogenesis, peak increases in iBAT
temperature and expired CO2 appear saturated at 150 µM
BIM-23627 when compared to control (iBAT: 1.38 ± 0.25 vs
−0.06 ± 0.03◦C, p < 0.01, n = 4; expired CO2: 0.32 ± 0.07
vs −0.02 ± 0.03%, p < 0.0001, n = 5, respectively),
as increasing doses of 450 µM (iBAT: 1.17 ± 0.16◦C,
p = 0.01, n = 5; expired CO2: 0.24 ± 0.03%, p < 0.01,
n = 7, respectively) and 1.5 mM (iBAT: 1.16 ± 0.48◦C,
p < 0.05; n = 4, expired CO2: 0.27 ± 0.04%, n = 4,
p < 0.01) did not significantly alter the peak responses
reached. Only peak increases were measured for iBAT and
expired CO2 as later changes could arise because of evoked
hemodynamic alterations.
To further corroborate SSTR2 involvement in setting
sympathetic, cardiovascular and thermogenic tone, the effect
of CYN-154806 (1 mM, n = 3) was determined (Figure 6C).
Although CYN-154806 evoked initial sympathoexcitatory
and hypertensive effects, these did not reach significance.
The sympathoinhibition and hypotension that followed,
however, reached significance when compared to control
(sSNA: −80.8 ± 18.6%, p < 0.05, MAP: −35.8 ± 6.03 mmHg,
p < 0.01, respectively). CYN-154806 administration also
resulted in significant tachycardia (37.3 ± 5.7 bpm, p < 0.01),
increased iBAT temperature (1.64 ± 0.34◦C, p < 0.01),
and increased expired CO2 (0.38 ± 0.19%, p < 0.05) when
compared to control.
In order to ascertain that the tachycardic and thermogenic
effects of BIM-23627 were not due to activation of SPN
innervating the adrenal gland resulting in catecholamine release
potentially activating adrenergic receptors that regulate the heart
and iBAT (Cannon and Nedergaard, 2004) the adrenal glands
were removed in two experiments. The effect of intrathecal
BIM-23627 at 1 mM was identical to the effects seen without
adrenalectomy (data not shown).
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FIGURE 4 | Premotor sympathetic neurons express preprosomatostatin (PPS) mRNA. (A–C) Premotor sympathetic regions (magenta boxes) showing CTB-ir
neurons retrogradely labeled from the spinal cord (green) and PPS mRNA expression (black). Double-labeled cells are indicated by arrowheads. (A) Raphe pallidus
(RPa) and raphe magnus (RMg), (B) Raphe obscurus (ROb) and raphe magnus (RMg), (C) Rostral ventromedial medulla (RVMM). Scale bars = 50 µm.
(D) Percentage of CTB immunoreactive cells containing PPS mRNA within each presympathetic region examined. Data are shown as mean ± SEM. Cell counts per
region are shown above each bar. Schematic diagrams adapted from Paxinos and Watson (2005).
DISCUSSION
We demonstrate that SST or SSTR2 agonist injected intrathecally
in thoracic spinal cord, modulates sympathetic, cardiovascular
and iBAT thermogenic tone. SSTR2-like immunoreactivity
was localized to subsets of SPN, dorsal horn neurons and
inhibitory interneurons. Importantly, we show that SSTR2
antagonists increase sympathetic, cardiac and iBAT thermogenic
tone suggesting that SST, tonically activating SST2R, in the
thoracic cord is required for the maintenance of sympathetic,
cardiovascular and thermogenic tone (at least in the anesthetized
preparation used here). SST potentially released from the RVMM
and raphe premotor nuclei may contribute to this.
Our data confirms and extends previous studies exploring
the distribution of SSTR2 in the spinal cord (Todd et al., 1998;
Schulz et al., 2000). Novel data reveal that SSTR2A-like
immunoreactivity and possibly SSTR2B-like immunoreactivity
were present on a subset of SPN, in line with the description
of SST terminals around SPN (Johansson et al., 1984; Krukoff,
1987). These data strongly support the idea that SST, released
at SSTR2, reduces sympathetic activity. Intrathecal injection
of SST, or the SSTR2 selective agonist Seglitide, did evoke
sympathoinhibition, hypotension, bradycardia, and decreased
iBAT temperature and expired CO2. These effects are in keeping
with the well-described inhibitory effects of SST on neurons
(Bou Farah et al., 2016; Gunther et al., 2018). We also found
PPS mRNA in subsets of sympathetic premotor neurons in all
major loci, predominantly from the midline raphe and RVMM
regions. This also corroborates earlier studies describing SST-
like immunoreactivity in the medullary raphe, RVMM and A5
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FIGURE 5 | Intrathecal SST and SSTR2 agonist decrease sympathetic, cardiovascular and thermogenic outflows. (A) Representative responses show that SST
(1 mM) elicited decreases in sSNA, MAP, HR, iBAT temperature and expired CO2. (B) The SSTR2 agonist seglitide evoked similar effects to SST. (C) Grouped data
showing peak responses evoked by intrathecal SST (n = 7), seglitide (n = 8) or vehicle (n = 8). Data are expressed as mean ± SEM. Effect of each drug compared to
vehicle ∗ = p < 0.05, ∗∗ = p < 0.01, ∗∗∗ = p < 0.001, ∗∗∗∗ = p < 0.0001.
noradrenergic neurons (Strack et al., 1989b; Jansen et al., 1995).
Taken together these data suggest it is possible that inhibitory SST
is released from sympathetic premotor neurons (thought to be
primarily excitatory) directly at SPN.
Surprisingly, we have demonstrated that SST acts tonically
at SSTR2 in the spinal cord, as intrathecal administration of
two selective SSTR2 antagonists evoked sympathoexcitation,
tachycardia, thermogenesis and an increase in end tidal CO2.
Administration of high doses of both antagonists produced
biphasic responses, where initial excitatory responses in all
outflows were followed by rapid and sustained decreases in
sympathetic and cardiovascular outflows before returning to
baseline. Several mechanisms are possible.
It is plausible that the SSTR2 antagonist induced excitatory
responses are evoked by removal of inhibitory SST directly at
the different pools of SPN regulating splanchnic SNA, the heart
and iBAT. Our data and that of others demonstrate that SST
terminals are present in the IML and that there are premotor
sympathetic and spinal (Jung et al., 2008) sources of SST that may
be tonically released.
It is also possible that the SSTR2 antagonist evoked increases
in HR, iBAT temperature and expired CO2 may be coordinated,
as low doses of BIM-23627 induced significant and large
effects in only these parameters and, such a response may
represent thermogenesis, as described previously (Morrison
and Madden, 2014). This may be produced directly at
SPN altering both HR and iBAT temperature, however, it
is likely that SSTR2 blockade prevents the actions of SST
tonically released in the dorsal horn, which occurs even
when no peripheral afferent stimulus is applied (Morton
et al., 1988). Thus, it is possible that temperature sensitive
peripheral inputs to dorsal horn neurons are gated by SST
released intraspinally and, when removed thermogenesis occurs.
The spinoparabrachial cold defense pathway (Morrison and
Madden, 2014) may be disinhibited by SSTR2 antagonists as
although SSTR2A are expressed on inhibitory dorsal horn
neurons (Todd et al., 1998) a spinoparabrachial population
of excitatory SSTR2A expressing neurons has been described
(Cameron et al., 2015).
The increase in splanchnic SNA generated by SSTR2 blockade
is unlikely related to thermogenesis as the effective antagonist
doses do not align and innervation of splanchnic and BAT
preganglionic neurons are independent. Therefore, a sympathetic
pathway driving functions activated by the splanchnic nerve
appears to be tonically inhibited by SST. As the splanchnic
nerve controls both vasomotor and gastrointestinal functions this
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FIGURE 6 | Effects of intrathecal SSTR2 antagonists on sympathetic, cardiovascular and thermogenic outflows. (A) Representative responses show that 150 and
450 µM of the SSTR2 antagonist BIM-23627 evoked increases in sSNA, MAP, HR, iBAT temperature and expired CO2. Higher doses (1.5 mM) of BIM-23627
elicited smaller early increases in sSNA, MAP, HR, iBAT temperature and expired CO2 followed immediately by large falls below baseline in sSNA, MAP and HR. IBAT
temperature also declined but not below baseline. (B) CYN-154806 (1 mM) evoked similar effects to BIM-23627. (C) Grouped data showing peak changes relative to
baseline with little to no effect seen with vehicle or 45 µM BIM-23627 (n = 2). In contrast 150 or 450 µM BIM-23627 evoked large early increases in all parameters.
Biphasic responses in SNA, MAP and HR were evident at doses greater than 150 µM BIM-23627. All doses of BIM-23627 (except 45 µM) and CYN-154806
increased iBAT temperature and expired CO2. Data are expressed mean ± SEM, asterisks denote significant difference compared to PBS control (∗ = p < 0.05,
∗∗ = p < 0.01, ∗∗∗ = p < 0.001, ∗∗∗∗ = p < 0.0001), and the octothorp denotes either significant linear or quadratic trends (# = p < 0.05, #### = p < 0.0001).
Frontiers in Neuroscience | www.frontiersin.org 10 February 2019 | Volume 13 | Article 121
fnins-13-00121 February 18, 2019 Time: 15:54 # 11
Bowman et al. SSTR2 Receptors in Spinal Cord
action may contribute to the increase in MAP that also occurs
following SST2R blockade.
Drug movement when applied intrathecally has been assessed
(Yaksh and Rudy, 1976; Nishio et al., 1989) and it is clear
that spinal cord regions impacted are influenced by catheter
placement, drug-type, concentration, speed of application
and time. Significant sympathoinhibition, hypotension and
bradycardia followed the early excitatory responses when higher
doses of SSTR2 antagonists were administered. These robust
responses recover within about 70 min, indicating a non-
neurotoxic effect. While there is some evidence for constitutive
activity in SST receptors in vitro (Ben-Shlomo et al., 2007,
2009) there is no evidence that the antagonists used here block
constitutive activity. Studies well suited to detecting inverse
agonists (i.e., GTPyS) do not report effects of the antagonists,
so constitutive activation of SSTR is a formal possibility,
however, available evidence is more consistent with reversal
of endogenous SST tone (Gunther et al., 2018). Both peptide
antagonists used here act competitively with high binding affinity
at SSTR2 (Bass et al., 1996; Feniuk et al., 2000; Tulipano
et al., 2002) and although previous data suggest an interaction
with opioid receptors (Ghosh et al., 1997), CYN-154806 does
not block µ-opioid mediated inhibition (Feniuk et al., 2000),
indicating that the observed effects are due to blockade of SSTR2.
The effects are consistent with the hypothesis that increasing
blockade of SSTR2 results in potent disinhibition by recruiting
a spinal GABAergic network that counteracts the enhanced
sympathetic and cardiovascular function. The delayed effect
and a higher dose of antagonists may be required to access
and disinhibit such a diffuse network, as blockade at more
than a few neurons in the network may be needed to drive
sympathoinhibition. A tonic GABAergic network is present in the
spinal cord regulating sympathetic and cardiovascular functions
(Deuchars et al., 2005; Goodchild et al., 2008; Bowman and
Goodchild, 2015) possibly via α5 GABA-A receptors (Wang
et al., 2008) and perhaps, this is regulated by SST. In keeping
with this idea GABAergic interneurons are responsible for about
half (Llewellyn-Smith, 2002) of the GABAergic boutons which
comprise about 50% of the innervation of SPN (Llewellyn-Smith
et al., 1995) and as demonstrated here and elsewhere (Todd, 2017)
GABAergic interneurons express SSTR2A. As primary afferents
only contribute about 40% of SST even in the dorsal horn
(Morton et al., 1989) the remainder arises from local intraspinal
(Proudlock et al., 1993) or supraspinal sources as described here.
CONCLUSION
The findings demonstrate that SSTR2-like immunoreactivity
is present on SPN, GABAergic interneurons and dorsal horn
neurons of the thoracic spinal cord and that exogenously applied
SST, or an SSTR2 agonist, reduce sympathetic, cardiovascular
and thermogenic activity. Blockade of endogenous SST signaling,
using selective SSTR2 antagonists, increased all parameters
measured with higher doses of antagonists then robustly reducing
sympathetic and cardiovascular parameters. Thus, acting at
multiple sites within the spinal cord, SST appears to act as a
“brake,” tonically inhibiting sympathetic and iBAT thermogenic
tone via SSTR2. The data are also consistent with the notion
that SST tonically modulates, via SSTR2, a diffuse GABAergic
network that impacts sympathetic and cardiovascular function
with the source/s of spinal SST having supra- and/or intra-
spinal origins.
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